Grifols (GIKLY) Total Non-Current Liabilities (2009 - 2025)

Grifols (GIKLY) posted Total Non-Current Liabilities of $11.7 billion for Q4 2025, up 3.27% quarter-over-quarter from $11.4 billion in Q4 2024, and up 3.27% year-on-year from $11.4 billion in Q4 2024.

Grifols (GIKLY) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends

Grifols (GIKLY) has reported Total Non-Current Liabilities for 16 consecutive years, with $11.7 billion the latest figure, recorded in Q4 2025.

  • Total Non-Current Liabilities for Q4 2025 came in at $11.7 billion, up 3.27% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.7 billion (up 3.27% YoY), and the FY2025 annual result was $11.7 billion, up 20873.57% from the prior year.
  • Total Non-Current Liabilities was $11.7 billion for Q4 2025 at Grifols, up from $11.4 billion in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $12.0 billion in Q4 2023 and troughed at $9.7 billion in Q4 2021.
  • Average Total Non-Current Liabilities over 5 years is $11.2 billion, with a median of $11.5 billion recorded in 2022.
  • Year-over-year, Total Non-Current Liabilities grew 18.68% in 2022 and retreated 5.22% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $9.7 billion in 2021, then grew by 18.68% to $11.5 billion in 2022, then increased by 4.7% to $12.0 billion in 2023, then fell by 5.22% to $11.4 billion in 2024, then increased by 3.27% to $11.7 billion in 2025.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $11.7 billion in Q4 2025, $11.4 billion in Q4 2024, and $12.0 billion in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 48.74 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 119.22 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 109.01 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -34.06 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 75.17 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 80.55 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 31.56 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 113.51 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - 100.00 Mn
10 Grifols - - - 11.75 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 11.75 Bn
Dec 31, 2024 11.37 Bn
Dec 31, 2023 12.00 Bn
Dec 31, 2022 11.46 Bn
Dec 31, 2021 9.66 Bn
Dec 31, 2020 8.61 Bn
Sep 30, 2020 8.52 Bn
Mar 31, 2020 8.12 Bn
Dec 31, 2019 8.11 Bn
Sep 30, 2019 8.18 Bn
Dec 31, 2018 7.45 Bn
Sep 30, 2018 7.61 Bn
Jun 30, 2018 7.69 Bn
Mar 31, 2018 8.96 Bn
Dec 31, 2017 7.43 Bn
Jun 30, 2017 7.29 Bn
Dec 31, 2016 5.75 Bn
Sep 30, 2016 5.70 Bn
Jun 30, 2016 5.82 Bn
Dec 31, 2015 5.75 Bn